Side effects include dry mouth, anorexia, insomnia, constipation and headache.
Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled substance in the United States. In October 2010, Sibutramine was withdrawn from Canadian and U.S. markets due to concerns that the drug increases the risk of heart attack and stroke in patients with a history of heart disease.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
Patients with this genotype will lose weight with sibutramine.
| Cyproheptadine | The therapeutic efficacy of Sibutramine can be decreased when used in combination with Cyproheptadine. |
| Desmopressin | The risk or severity of hyponatremia can be increased when Sibutramine is combined with Desmopressin. |
| Ioflupane I-123 | Sibutramine may decrease effectiveness of Ioflupane I-123 as a diagnostic agent. |
| Linezolid | The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Sibutramine. |
| Metyrosine | The risk or severity of extrapyramidal symptoms can be increased when Metyrosine is combined with Sibutramine. |
| Pimozide | The risk or severity of QTc prolongation can be increased when Sibutramine is combined with Pimozide. |
| Buprenorphine | Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Sibutramine. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Sibutramine. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Sibutramine. |
| Hydrocodone | Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Sibutramine. |
| Magnesium sulfate | The therapeutic efficacy of Sibutramine can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Sibutramine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Sibutramine. |
| Orphenadrine | Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Sibutramine. |
| Pramipexole | Sibutramine may increase the sedative activities of Pramipexole. |
| Ropinirole | Sibutramine may increase the sedative activities of Ropinirole. |
| Rotigotine | Sibutramine may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Sibutramine. |
| Sodium oxybate | Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Sibutramine. |
| Thalidomide | Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Metoclopramide | The risk or severity of adverse effects can be increased when Metoclopramide is combined with Sibutramine. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Sibutramine. |
| Tedizolid phosphate | The risk or severity of serotonin syndrome can be increased when Tedizolid phosphate is combined with Sibutramine. |
| Acetylsalicylic acid | Sibutramine may increase the antiplatelet activities of Acetylsalicylic acid. |
| Mirtazapine | Sibutramine may increase the serotonergic activities of Mirtazapine. |
| Morphine | The risk or severity of serotonin syndrome can be increased when Morphine is combined with Sibutramine. |
| Hydromorphone | The risk or severity of serotonin syndrome can be increased when Hydromorphone is combined with Sibutramine. |
| Oxycodone | The risk or severity of serotonin syndrome can be increased when Oxycodone is combined with Sibutramine. |
| Butorphanol | The risk or severity of serotonin syndrome can be increased when Butorphanol is combined with Sibutramine. |
| Dextropropoxyphene | The risk or severity of serotonin syndrome can be increased when Dextropropoxyphene is combined with Sibutramine. |
| Pentazocine | The risk or severity of serotonin syndrome can be increased when Pentazocine is combined with Sibutramine. |
| Sufentanil | The risk or severity of serotonin syndrome can be increased when Sufentanil is combined with Sibutramine. |
| Nalbuphine | The risk or severity of serotonin syndrome can be increased when Nalbuphine is combined with Sibutramine. |
| Levorphanol | The risk or severity of serotonin syndrome can be increased when Levorphanol is combined with Sibutramine. |
| Remifentanil | The risk or severity of serotonin syndrome can be increased when Remifentanil is combined with Sibutramine. |
| Diphenoxylate | The risk or severity of serotonin syndrome can be increased when Diphenoxylate is combined with Sibutramine. |
| Oxymorphone | The risk or severity of serotonin syndrome can be increased when Oxymorphone is combined with Sibutramine. |
| Dezocine | The risk or severity of serotonin syndrome can be increased when Dezocine is combined with Sibutramine. |
| Methadyl acetate | The risk or severity of serotonin syndrome can be increased when Methadyl acetate is combined with Sibutramine. |
| Dihydroetorphine | The risk or severity of serotonin syndrome can be increased when Dihydroetorphine is combined with Sibutramine. |
| Diamorphine | The risk or severity of serotonin syndrome can be increased when Diamorphine is combined with Sibutramine. |
| Ethylmorphine | The risk or severity of serotonin syndrome can be increased when Ethylmorphine is combined with Sibutramine. |
| Etorphine | The risk or severity of serotonin syndrome can be increased when Etorphine is combined with Sibutramine. |
| Dextromoramide | The risk or severity of serotonin syndrome can be increased when Dextromoramide is combined with Sibutramine. |
| Desomorphine | The risk or severity of serotonin syndrome can be increased when Desomorphine is combined with Sibutramine. |
| Carfentanil | The risk or severity of serotonin syndrome can be increased when Carfentanil is combined with Sibutramine. |
| Dihydrocodeine | The risk or severity of serotonin syndrome can be increased when Dihydrocodeine is combined with Sibutramine. |
| Alphacetylmethadol | The risk or severity of serotonin syndrome can be increased when Alphacetylmethadol is combined with Sibutramine. |
| Dihydromorphine | The risk or severity of serotonin syndrome can be increased when Dihydromorphine is combined with Sibutramine. |
| Ketobemidone | The risk or severity of serotonin syndrome can be increased when Ketobemidone is combined with Sibutramine. |
| DPDPE | The risk or severity of serotonin syndrome can be increased when DPDPE is combined with Sibutramine. |
| Lofentanil | The risk or severity of serotonin syndrome can be increased when Lofentanil is combined with Sibutramine. |
| Opium | The risk or severity of serotonin syndrome can be increased when Opium is combined with Sibutramine. |
| Normethadone | The risk or severity of serotonin syndrome can be increased when Normethadone is combined with Sibutramine. |
| Piritramide | The risk or severity of serotonin syndrome can be increased when Piritramide is combined with Sibutramine. |
| Alphaprodine | The risk or severity of serotonin syndrome can be increased when Alphaprodine is combined with Sibutramine. |
| Meptazinol | The risk or severity of serotonin syndrome can be increased when Meptazinol is combined with Sibutramine. |
| Phenoperidine | The risk or severity of serotonin syndrome can be increased when Phenoperidine is combined with Sibutramine. |
| Phenazocine | The risk or severity of serotonin syndrome can be increased when Phenazocine is combined with Sibutramine. |
| Tilidine | The risk or severity of serotonin syndrome can be increased when Tilidine is combined with Sibutramine. |
| Carfentanil, C-11 | The risk or severity of serotonin syndrome can be increased when Carfentanil, C-11 is combined with Sibutramine. |
| Naltrexone | The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Sibutramine. |
| Bezitramide | The risk or severity of serotonin syndrome can be increased when Bezitramide is combined with Sibutramine. |
| Eluxadoline | The risk or severity of serotonin syndrome can be increased when Eluxadoline is combined with Sibutramine. |
| Nicomorphine | The risk or severity of serotonin syndrome can be increased when Nicomorphine is combined with Sibutramine. |
| Codeine | The risk or severity of serotonin syndrome can be increased when Codeine is combined with Sibutramine. |
| Meperidine | The risk or severity of serotonin syndrome can be increased when Meperidine is combined with Sibutramine. |
| Alfentanil | The risk or severity of serotonin syndrome can be increased when Alfentanil is combined with Sibutramine. |
| Fentanyl | The risk or severity of serotonin syndrome can be increased when Fentanyl is combined with Sibutramine. |
| Levacetylmethadol | The risk or severity of serotonin syndrome can be increased when Levacetylmethadol is combined with Sibutramine. |
| Benzhydrocodone | The risk or severity of serotonin syndrome can be increased when Benzhydrocodone is combined with Sibutramine. |
| Naloxegol | The risk or severity of serotonin syndrome can be increased when Naloxegol is combined with Sibutramine. |
| Iobenguane | Sibutramine may decrease effectiveness of Iobenguane as a diagnostic agent. |
| Methyclothiazide | The risk or severity of hyponatremia can be increased when Sibutramine is combined with Methyclothiazide. |
| Chlorthalidone | The risk or severity of hyponatremia can be increased when Sibutramine is combined with Chlorthalidone. |
| Bendroflumethiazide | The risk or severity of hyponatremia can be increased when Sibutramine is combined with Bendroflumethiazide. |
| Metolazone | The risk or severity of hyponatremia can be increased when Sibutramine is combined with Metolazone. |
| Benzthiazide | The risk or severity of hyponatremia can be increased when Sibutramine is combined with Benzthiazide. |
| Hydroflumethiazide | The risk or severity of hyponatremia can be increased when Sibutramine is combined with Hydroflumethiazide. |
| Indapamide | The risk or severity of hyponatremia can be increased when Sibutramine is combined with Indapamide. |
| Chlorothiazide | The risk or severity of hyponatremia can be increased when Sibutramine is combined with Chlorothiazide. |
| Hydrochlorothiazide | The risk or severity of hyponatremia can be increased when Sibutramine is combined with Hydrochlorothiazide. |
| Trichlormethiazide | The risk or severity of hyponatremia can be increased when Sibutramine is combined with Trichlormethiazide. |
| Polythiazide | The risk or severity of hyponatremia can be increased when Sibutramine is combined with Polythiazide. |
| Quinethazone | The risk or severity of hyponatremia can be increased when Sibutramine is combined with Quinethazone. |
| Cyclopenthiazide | The risk or severity of hyponatremia can be increased when Sibutramine is combined with Cyclopenthiazide. |
| Epitizide | The risk or severity of hyponatremia can be increased when Sibutramine is combined with Epitizide. |
| Ethanol | Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Sibutramine. |
| Botulinum toxin type B | The risk or severity of adverse effects can be increased when Botulinum toxin type B is combined with Sibutramine. |
| Botulinum toxin type A | The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Sibutramine. |